Prothena Corporation plc (PRTA)
| Market Cap | 595.90M |
| Revenue (ttm) | 11.79M |
| Net Income (ttm) | -280.46M |
| Shares Out | 53.83M |
| EPS (ttm) | -5.21 |
| PE Ratio | n/a |
| Forward PE | 102.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,643 |
| Open | 11.18 |
| Previous Close | 11.16 |
| Day's Range | 10.98 - 11.48 |
| 52-Week Range | 4.32 - 17.66 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 18.86 (+70.37%) |
| Earnings Date | Nov 6, 2025 |
About PRTA
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potent... [Read more]
Financial Performance
In 2024, Prothena Corporation's revenue was $135.16 million, an increase of 47.92% compared to the previous year's $91.37 million. Losses were -$122.31 million, -16.81% less than in 2023.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price target is $18.86, which is an increase of 70.37% from the latest price.
News
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.
Prothena to Report Third Quarter 2025 Financial Results on November 6
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its third quarter 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
Prothena Q2 Revenue Drops 97%
Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker...
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.
Prothena to Report Second Quarter 2025 Financial Results on August 4
DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.
Prothena Announces Corporate Restructuring
DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.
Why Is Prothena Stock Trading Lower On Tuesday?
Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.
Prothena to Report First Quarter 2025 Financial Results on May 8
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President a...
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance.
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breac...
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025.
Prothena Announces Board of Directors Update
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors.
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease.
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.